S&P 500   4,418.66 (+1.43%)
DOW   34,609.69 (+0.91%)
QQQ   352.03 (+2.01%)
AAPL   162.65 (+1.80%)
MSFT   300.82 (+4.27%)
FB   301.21 (+0.35%)
GOOGL   2,624.02 (+3.36%)
AMZN   2,823.88 (+0.86%)
TSLA   951.07 (+3.56%)
NVDA   232.20 (+4.01%)
BABA   116.71 (-2.04%)
NIO   23.58 (-0.88%)
AMD   113.83 (+2.43%)
CGC   7.53 (+2.31%)
MU   83.31 (+3.21%)
GE   90.65 (-0.50%)
T   25.78 (-2.64%)
F   20.31 (+1.65%)
DIS   137.68 (+0.86%)
AMC   16.40 (+2.37%)
PFE   53.11 (+1.08%)
ACB   4.27 (+1.43%)
BA   198.45 (-2.77%)
S&P 500   4,418.66 (+1.43%)
DOW   34,609.69 (+0.91%)
QQQ   352.03 (+2.01%)
AAPL   162.65 (+1.80%)
MSFT   300.82 (+4.27%)
FB   301.21 (+0.35%)
GOOGL   2,624.02 (+3.36%)
AMZN   2,823.88 (+0.86%)
TSLA   951.07 (+3.56%)
NVDA   232.20 (+4.01%)
BABA   116.71 (-2.04%)
NIO   23.58 (-0.88%)
AMD   113.83 (+2.43%)
CGC   7.53 (+2.31%)
MU   83.31 (+3.21%)
GE   90.65 (-0.50%)
T   25.78 (-2.64%)
F   20.31 (+1.65%)
DIS   137.68 (+0.86%)
AMC   16.40 (+2.37%)
PFE   53.11 (+1.08%)
ACB   4.27 (+1.43%)
BA   198.45 (-2.77%)
S&P 500   4,418.66 (+1.43%)
DOW   34,609.69 (+0.91%)
QQQ   352.03 (+2.01%)
AAPL   162.65 (+1.80%)
MSFT   300.82 (+4.27%)
FB   301.21 (+0.35%)
GOOGL   2,624.02 (+3.36%)
AMZN   2,823.88 (+0.86%)
TSLA   951.07 (+3.56%)
NVDA   232.20 (+4.01%)
BABA   116.71 (-2.04%)
NIO   23.58 (-0.88%)
AMD   113.83 (+2.43%)
CGC   7.53 (+2.31%)
MU   83.31 (+3.21%)
GE   90.65 (-0.50%)
T   25.78 (-2.64%)
F   20.31 (+1.65%)
DIS   137.68 (+0.86%)
AMC   16.40 (+2.37%)
PFE   53.11 (+1.08%)
ACB   4.27 (+1.43%)
BA   198.45 (-2.77%)
S&P 500   4,418.66 (+1.43%)
DOW   34,609.69 (+0.91%)
QQQ   352.03 (+2.01%)
AAPL   162.65 (+1.80%)
MSFT   300.82 (+4.27%)
FB   301.21 (+0.35%)
GOOGL   2,624.02 (+3.36%)
AMZN   2,823.88 (+0.86%)
TSLA   951.07 (+3.56%)
NVDA   232.20 (+4.01%)
BABA   116.71 (-2.04%)
NIO   23.58 (-0.88%)
AMD   113.83 (+2.43%)
CGC   7.53 (+2.31%)
MU   83.31 (+3.21%)
GE   90.65 (-0.50%)
T   25.78 (-2.64%)
F   20.31 (+1.65%)
DIS   137.68 (+0.86%)
AMC   16.40 (+2.37%)
PFE   53.11 (+1.08%)
ACB   4.27 (+1.43%)
BA   198.45 (-2.77%)
OTCMKTS:CVSI

CV Sciences Stock Competitors

$0.15
+0.01 (+7.86%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.13
$0.15
50-Day Range
$0.10
$0.26
52-Week Range
$0.10
$1.12
Volume
350,650 shs
Average Volume
1.23 million shs
Market Capitalization
$17.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.86

CV Sciences (OTCMKTS:CVSI) Vs. HTBX, GRTX, ORPH, LTRN, LUMO, OSMT, AKTX, EVFM, RZLT, and MACK

Should you be buying CV Sciences stock or one of its competitors? The main competitors of CV Sciences include Heat Biologics (HTBX), Galera Therapeutics (GRTX), Orphazyme A/S (ORPH), Lantern Pharma (LTRN), Lumos Pharma (LUMO), Osmotica Pharmaceuticals (OSMT), Akari Therapeutics (AKTX), Evofem Biosciences (EVFM), Rezolute (RZLT), and Merrimack Pharmaceuticals (MACK). These companies are all part of the "pharmaceutical preparations" industry.

CV Sciences vs.

Galera Therapeutics (NASDAQ:GRTX) and CV Sciences (OTCMKTS:CVSI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Galera Therapeutics has a net margin of 0.00% compared to CV Sciences' net margin of -78.86%. Galera Therapeutics' return on equity of 0.00% beat CV Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Galera Therapeutics N/A N/A -90.93%
CV Sciences -78.86% -144.40% -56.74%

In the previous week, CV Sciences had 1 more articles in the media than Galera Therapeutics. MarketBeat recorded 1 mentions for CV Sciences and 0 mentions for Galera Therapeutics. Galera Therapeutics' average media sentiment score of 0.00 equaled CV Sciences' average media sentiment score.

Company Overall Sentiment
Galera Therapeutics Neutral
CV Sciences Neutral

Galera Therapeutics presently has a consensus target price of $12.40, suggesting a potential upside of 360.97%. CV Sciences has a consensus target price of $0.42, suggesting a potential upside of 180.54%. Given Galera Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Galera Therapeutics is more favorable than CV Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galera Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
CV Sciences
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

CV Sciences received 171 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 66.56% of users gave CV Sciences an outperform vote while only 59.46% of users gave Galera Therapeutics an outperform vote.

CompanyUnderperformOutperform
Galera TherapeuticsOutperform Votes
44
59.46%
Underperform Votes
30
40.54%
CV SciencesOutperform Votes
215
66.56%
Underperform Votes
108
33.44%

CV Sciences has higher revenue and earnings than Galera Therapeutics. CV Sciences is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A-$74.22 million-$3.29-0.82
CV Sciences$24.43 million0.74-$22.28 million-$0.15-1.01

76.2% of Galera Therapeutics shares are held by institutional investors. Comparatively, 0.0% of CV Sciences shares are held by institutional investors. 19.6% of Galera Therapeutics shares are held by company insiders. Comparatively, 6.8% of CV Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Galera Therapeutics has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, CV Sciences has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Summary

Galera Therapeutics beats CV Sciences on 9 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CV Sciences (OTCMKTS:CVSI) vs. Its Competitors

TypeCV SciencesPharmaceutical IndustryMedical SectorOTCMKTS Exchange
Market Cap$17.97M$5.60B$4.55B$7.22B
Dividend YieldN/A2.57%2.07%36.30%
P/E Ratio-1.0113.3416.462.24
Price / Sales0.74491.625,535.44441.01
Price / CashN/A162.3360.5931.13
Price / Book1.378.477.475.25
Net Income-$22.28M$98.83M$98.49M$426.40M
7 Day Performance-9.10%-3.61%-3.59%-2.10%
1 Month Performance25.75%-18.64%-13.66%109.36%
1 Year Performance-75.46%-34.10%-22.17%68.90%

CV Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HTBX
Heat Biologics
1.95 of 5 stars
$2.81
+2.8%
$16.75
+496.1%
-66.0%$71.39M$2.95M0.0039Analyst Report
Gap Up
GRTX
Galera Therapeutics
2.4381 of 5 stars
$2.69
+1.1%
$12.40
+361.0%
-76.8%$71.12MN/A-0.8238Gap Up
ORPH
Orphazyme A/S
1.4765 of 5 stars
$2.03
+2.5%
$5.00
+146.3%
-85.7%$70.95MN/A0.00141Negative News
Gap Up
LTRN
Lantern Pharma
2.0333 of 5 stars
$6.30
+2.9%
$31.50
+400.0%
-58.4%$70.48MN/A-4.9213Gap Up
LUMO
Lumos Pharma
2.1583 of 5 stars
$8.41
+5.1%
$28.00
+232.9%
-58.6%$70.28M$170K-2.5629
OSMT
Osmotica Pharmaceuticals
2.2231 of 5 stars
$1.11
+1.8%
$6.00
+440.5%
-75.9%$69.47M$177.88M-0.70302
AKTX
Akari Therapeutics
1.2664 of 5 stars
$1.33
+3.0%
N/A-56.1%$69.04MN/A-2.612,020
EVFM
Evofem Biosciences
1.9914 of 5 stars
$0.42
+2.4%
$1.50
+255.5%
-85.9%$68.85M$450K-0.23147Gap Up
RZLT
Rezolute
2.0333 of 5 stars
$4.41
+3.6%
$21.25
+381.9%
-71.8%$68.09MN/A-1.4623Gap Up
MACK
Merrimack Pharmaceuticals
1.7931 of 5 stars
$5.00
+8.0%
N/A-39.1%$67.05MN/A-21.7427News Coverage
Gap Up
APM
Aptorum Group
0.9064 of 5 stars
$1.87
+20.3%
N/A-34.0%$66.59M$910K0.0025Gap Down
DMAC
DiaMedica Therapeutics
1.8598 of 5 stars
$2.51
+2.0%
$20.50
+716.7%
-73.6%$66.36MN/A-3.2611News Coverage
LCI
Lannett
2.3398 of 5 stars
$1.52
+0.0%
$6.00
+294.7%
-80.8%$65.82M$478.78M-0.16954Upcoming Earnings
News Coverage
LBPS
4D pharma
2.1583 of 5 stars
$4.00
+0.3%
$37.50
+837.5%
N/A$65.73M$690K-10.812,020News Coverage
Positive News
LTUS
Lotus Pharmaceuticals
0 of 5 stars
$0.02
+0.0%
N/A+21.8%$64.78MN/A0.00533
ITRM
Iterum Therapeutics
1.7265 of 5 stars
$0.35
+2.8%
$0.70
+101.4%
-81.5%$63.06M$40K-0.337Gap Up
NEPT
Neptune Wellness Solutions
1.7798 of 5 stars
$0.37
+0.2%
$1.13
+203.4%
-80.0%$62.08M$35.45M-0.4058Positive News
CRBP
Corbus Pharmaceuticals
1.7364 of 5 stars
$0.49
+2.4%
$2.50
+411.0%
-76.4%$61.26M$3.94M-1.1976Gap Up
ORGS
Orgenesis
0 of 5 stars
$2.50
+1.6%
N/A-62.8%$60.69M$7.65M0.00111
LBPH
Longboard Pharmaceuticals
1.7731 of 5 stars
$4.45
+2.5%
$31.33
+604.1%
N/A$60.46MN/A0.006Gap Down
NOVN
Novan
1.5265 of 5 stars
$3.20
+1.3%
$7.00
+118.8%
N/A$60.21M$4.92M-1.5823
CMMB
Chemomab Therapeutics
2.0798 of 5 stars
$5.28
+1.1%
$39.00
+638.6%
N/A$60.20MN/A-1.112,020Gap Up
SPRB
Spruce Biosciences
2.2314 of 5 stars
$2.56
+0.8%
$10.60
+314.1%
-88.5%$60.07MN/A-1.4217Analyst Report
News Coverage
GLYC
GlycoMimetics
2.2581 of 5 stars
$1.15
+1.7%
$6.50
+465.2%
-72.4%$59.50M$10.16M-0.9454
OTLC
Oncotelic Therapeutics
1.4583 of 5 stars
$0.16
+0.0%
N/AN/A$59.43M$1.74M0.0015
CYAD
Celyad Oncology
1.6564 of 5 stars
$3.69
+3.8%
$12.00
+225.2%
-56.2%$59.39M$10K0.0083Gap Up
CLVR
Clever Leaves
1.9917 of 5 stars
$2.20
+12.7%
$6.00
+172.7%
-79.4%$59.22M$12.12M0.00477News Coverage
Gap Up
BFRI
Biofrontera
1.825 of 5 stars
$3.46
+1.7%
$15.50
+348.0%
N/A$59.18MN/A0.002,021Analyst Upgrade
News Coverage
TYME
Tyme Technologies
1.5048 of 5 stars
$0.34
+54.5%
N/A-73.5%$59.08MN/A-2.1418News Coverage
Gap Down
PCSA
Processa Pharmaceuticals
2.2464 of 5 stars
$3.75
+5.3%
$22.00
+486.7%
-45.4%$58.94MN/A-1.6914News Coverage
Gap Up
GLTO
Galecto
2.1515 of 5 stars
$2.31
+4.8%
$11.50
+397.8%
-82.5%$58.36MN/A0.0028Gap Up
ATXS
Catabasis Pharmaceuticals
2.5764 of 5 stars
$4.48
+1.3%
$23.00
+413.4%
-72.5%$58.28MN/A-0.0820
ACRX
AcelRx Pharmaceuticals
1.7581 of 5 stars
$0.48
+0.8%
$5.00
+936.1%
-80.1%$57.58M$5.42M-1.4654
EDSA
Edesa Biotech
2.1181 of 5 stars
$4.25
+0.9%
$16.00
+276.5%
-22.4%$57.46M$330K-3.9412
KALA
Kala Pharmaceuticals
2.4981 of 5 stars
$0.88
+1.5%
$7.50
+755.5%
-87.5%$57.42M$6.36M-0.43188
ZSAN
Zosano Pharma
1.9781 of 5 stars
$0.48
+0.6%
$2.25
+368.3%
-55.0%$56.87M$220K-1.6645Gap Up
BPTS
Biophytis
1 of 5 stars
$4.59
+0.4%
N/AN/A$55.43MN/A0.002,020
CYCN
Cyclerion Therapeutics
1.9964 of 5 stars
$1.24
+0.0%
$10.50
+746.8%
-62.7%$53.71M$2.30M0.0051Analyst Downgrade
News Coverage
Gap Up
ELDN
Eledon Pharmaceuticals
2.2498 of 5 stars
$3.74
+0.8%
$27.67
+639.8%
-76.8%$53.51MN/A0.0010Analyst Upgrade
ACST
Acasti Pharma
1.7581 of 5 stars
$1.21
+1.2%
$6.00
+397.9%
-80.4%$53.37M$200K-2.6832
GANX
Gain Therapeutics
1.6248 of 5 stars
$4.45
+2.7%
$27.00
+506.7%
N/A$52.87M$30K0.0016Positive News
Gap Up
OCUP
Ocuphire Pharma
2.0531 of 5 stars
$3.02
+1.0%
$22.75
+653.3%
-74.5%$52.25MN/A0.005Gap Up
CPIX
Cumberland Pharmaceuticals
1.4665 of 5 stars
$3.46
+0.6%
N/A+5.5%$51.24M$37.44M-86.5090Gap Up
SNPX
Synaptogenix
0 of 5 stars
$7.66
+1.6%
N/AN/A$51.12MN/A0.004
COCP
Cocrystal Pharma
1.7581 of 5 stars
$0.52
+4.1%
$4.50
+760.4%
-75.2%$50.98M$2.01M-4.0213Gap Up
OGEN
Oragenics
0.9064 of 5 stars
$0.44
+1.3%
N/AN/A$50.75MN/A-2.567Gap Up
MRKR
Marker Therapeutics
2.0381 of 5 stars
$0.60
+4.0%
$6.67
+1,003.6%
-71.6%$50.19M$470K-0.9744Gap Up
ENSC
Ensysce Biosciences
2.0333 of 5 stars
$2.01
+2.0%
$4.00
+99.0%
N/A$48.76MN/A0.004Gap Up
IGXT
IntelGenx Technologies
1.0464 of 5 stars
$0.32
+3.4%
N/A+29.1%$48.18M$1.54M-4.574News Coverage
APRE
Aprea Therapeutics
1.7832 of 5 stars
$2.24
+0.0%
$4.00
+78.6%
-60.7%$48.08MN/A-1.0617
This page was last updated on 1/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.